Targets › ALK2
1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Jul 2027.
Open in Phaseline: the race on ALK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Incyte | INCB000928 ALK2 (activin receptor-like kinase 2) inhibitor | ALK2 | Phase 2 | Fibrodysplasia Ossificans Progressiva (FOP) | Jul 2027 |
Fibrodysplasia Ossificans Progressiva (FOP) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.